...
首页> 外文期刊>Journal of Medicinal Chemistry >3-Aryl(1,2,4)triazino(4,3-a)benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.
【24h】

3-Aryl(1,2,4)triazino(4,3-a)benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.

机译:3-Aryl(1,2,4)triazino(4,3-a)benzimidazol-4(10H)-ones:一类新型的选择性A1腺苷受体拮抗剂。

获取原文
获取原文并翻译 | 示例

摘要

Radioligand binding assays using bovine cortical membrane preparations and biochemical in vitro studies revealed that various 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one (ATBI) derivatives, previously reported by us as ligands of the central benzodiazepine receptor (BzR) (Primofiore, G.; et al. J. Med. Chem. 2000, 43, 96-102), behaved as antagonists at the A1 adenosine receptor (A1AR). Alkylation of the nitrogen at position 10 of the triazinobenzimidazole nucleus conferred selectivity for the A1AR vs the BzR. The most potent ligand of the ATBI series (10-methyl-3-phenyl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one 12) displayed a Ki value of 63 nM at the A1AR without binding appreciably to the adenosine A2A and A3 nor to the benzodiazepine receptor. Pharmacophore-based modeling studies in which 12 was compared against a set of well-established A1AR antagonists suggested that three hydrogen bonding sites (HB1 acceptor, HB2 and HB3 donors) and three lipophilic pockets (L1, L2, and L3) might be available to antagonists within the A1AR binding cleft. According to the proposed pharmacophore scheme, the lead compound 12 engages interactions with the HB2 site (via the N2 nitrogen) as well as with the L2 and L3 sites (through the pendant and the fused benzene rings). The results of these studies prompted the replacement of the methyl with more lipophilic groups at the 10-position (to fill the putative L1 lipophilic pocket) as a strategy to improve A1AR affinity. Among the new compounds synthesized and tested, the 3,10-diphenyl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one (23) was characterized by a Ki value of 18 nM which represents a 3.5-fold gain of A1AR affinity compared with the lead 12. A rhodopsin-based model of the bovine adenosine A1AR was built to highlight the binding mode of 23 and two well-known A1AR antagonists (III and VII) and to guide future lead optimization projects. In our docking simulations, 23 receives a hydrogen bond (via the N1 nitrogen) from the side chain of Asn247 (corresponding to the HB1 and HB2 sites) and fills the L1, L2, and L3 lipophilic pockets with the 10-phenyl, 3-phenyl, and fused benzene rings, respectively.
机译:放射性配体结合测定使用牛皮层膜制剂和生物化学体外研究表明,以前报道过各种3-芳基[1,2,4]三嗪[4,3-a]苯并咪唑-4(10H)-one(ATBI)衍生物。我们作为中央苯并二氮杂receptor受体(BzR)的配体(Primofiore,G .;等人,J.Med.Chem.2000,43,96-102),在A1腺苷受体(A1AR)上充当拮抗剂。在三嗪基苯并咪唑核的10位上的氮烷基化赋予A1AR对BzR选择性。 ATBI系列中最有效的配体(10-甲基-3-苯基[1,2,4]三嗪基[4,3-a]苯并咪唑-4(10H)-一个12)在反应中的Ki值为63 nM。 A1AR没有明显地与腺苷A2A和A3或苯并二氮杂binding受体结合。基于药理学的模型研究将12个与一组公认的A1AR拮抗剂进行了比较,表明三个氢键合位点(HB1受体,HB2和HB3供体)和三个亲脂性口袋(L1,L2和L3)可用于A1AR结合内的拮抗剂分裂。根据提出的药效团方案,铅化合物12与HB2位点(通过N2氮)以及与L2和L3位点(通过侧基和稠合苯环)相互作用。这些研究的结果促使在10位上用更多的亲脂性基团取代甲基(以填补假定的L1亲脂性口袋),作为提高A1AR亲和力的策略。在合成和测试的新化合物中,3,10-二苯基[1,2,4]三嗪基[4,3-a]苯并咪唑-4(10H)-one(23)的Ki值为18 nM,代表与前导12相比,A1AR亲和力提高了3.5倍。建立了基于视紫红质的牛腺苷A1AR模型,以突出23种和两种著名的A1AR拮抗剂(III和VII)的结合模式并指导未来领导优化项目。在我们的对接模拟中,23从Asn247的侧链(对应于HB1和HB2位点)接收氢键(通过N1氮),并用10-苯基,3-苯填充L1,L2和L3亲脂性口袋。苯环和稠合苯环。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号